These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11826742)

  • 1. [Evidence-based therapy of systemic sclerosis].
    Genth E
    Z Rheumatol; 2001 Dec; 60(6):464-8. PubMed ID: 11826742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic sclerosis].
    Tamborrini G; Distler M; Distler O
    Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of DMARDs in systemic sclerosis therapy.
    Blank N; Max R; Lorenz HM
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii42-4. PubMed ID: 16987834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive therapies in systemic sclerosis.
    Riemekasten G; Sunderkötter C
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii49-51. PubMed ID: 16987836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy.
    Strange G; Nash P
    Int J Rheum Dis; 2009 Sep; 12(3):192-206. PubMed ID: 20374346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
    Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
    Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and localized scleroderma.
    Chung L; Lin J; Furst DE; Fiorentino D
    Clin Dermatol; 2006; 24(5):374-92. PubMed ID: 16966019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
    Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis.
    Lin AT; Clements PJ; Furst DE
    Rheum Dis Clin North Am; 2003 May; 29(2):409-26. PubMed ID: 12841302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for the cutaneous manifestations of systemic sclerosis.
    Dutz J
    Skin Therapy Lett; 2000; 6(1):3-5. PubMed ID: 11027421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative therapies for systemic sclerosis.
    Ong VH; Denton CP
    Curr Opin Rheumatol; 2010 May; 22(3):264-72. PubMed ID: 20190640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of scleroderma].
    Mouthon L
    Rev Prat; 2002 Nov; 52(17):1915-7. PubMed ID: 12532869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach.
    Winterhalter S; Niehues T
    Klin Padiatr; 2008; 220(6):342-7. PubMed ID: 18949668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
    Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.